Wolfgang F Richter
Overview
Explore the profile of Wolfgang F Richter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
673
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Menochet K, Yu H, Wang B, Tibbitts J, Hsu C, Kamath A, et al.
MAbs
. 2022 Nov;
14(1):2145997.
PMID: 36418217
Monoclonal antibodies (mAbs) deliver great benefits to patients with chronic and/or severe diseases thanks to their strong specificity to the therapeutic target. As a result of this specificity, non-human primates...
2.
Bordeau B, Polli J, Schweser F, Grimm H, Richter W, Balthasar J
Int J Mol Sci
. 2022 Jan;
23(2).
PMID: 35054865
The prediction of monoclonal antibody (mAb) disposition within solid tumors for individual patients is difficult due to inter-patient variability in tumor physiology. Improved a priori prediction of mAb pharmacokinetics in...
3.
Frances N, Bacac M, Bray-French K, Christen F, Hinton H, Husar E, et al.
J Pharm Sci
. 2021 Dec;
111(4):1208-1218.
PMID: 34953862
We present a novel approach for first-in-human (FIH) dose selection of the CD20xCD3 bispecific antibody, glofitamab, based on pharmacokinetic/pharmacodynamic (PKPD) assessment in cynomolgus monkeys to select a high, safe starting...
4.
Liu S, Verma A, Kettenberger H, Richter W, Shah D
MAbs
. 2021 Oct;
13(1):1993769.
PMID: 34711143
A growing body of evidence supports the important role of molecular charge on antibody pharmacokinetics (PK), yet a quantitative description of the effect of charge on systemic and tissue disposition...
5.
Kissner T, Blaich G, Baumann A, Kronenberg S, Hey A, Kiessling A, et al.
MAbs
. 2021 Jul;
13(1):1938796.
PMID: 34241561
New challenges and other topics in non-clinical safety testing of biotherapeutics were presented and discussed at the nineth European BioSafe Annual General Membership meeting in November 2019. The session topics...
6.
Hey A, Baumann A, Kronenberg S, Blaich G, Mohl S, Fagg R, et al.
Int J Toxicol
. 2021 Feb;
40(3):270-284.
PMID: 33631988
Safety assessment of biological drugs has its challenges due to the multiple new different modalities, for example, antibody-drug conjugates, bispecifics, nanobodies, fusion proteins and advanced therapy medicinal products (ATMPs), their...
7.
Geiger M, Stubenrauch K, Sam J, Richter W, Jordan G, Eckmann J, et al.
Nat Commun
. 2020 Jun;
11(1):3196.
PMID: 32581215
T-cell bispecific antibodies (TCBs) crosslink tumor and T-cells to induce tumor cell killing. While TCBs are very potent, on-target off-tumor toxicity remains a challenge when selecting targets. Here, we describe...
8.
Richter W, Grimm H, Gouy M, Sogaard S, Kreuzer C, Wessels U, et al.
AAPS J
. 2020 Apr;
22(3):63.
PMID: 32246215
Minipigs have been proposed as animal model to study the subcutaneous (SC) absorption of monoclonal antibodies (mAb), because they are more translatable to humans than other species. However, the minipig...
9.
Kraft T, Richter W, Emrich T, Knaupp A, Schuster M, Wolfert A, et al.
MAbs
. 2019 Nov;
12(1):1683432.
PMID: 31769731
The pharmacokinetic (PK) properties of therapeutic antibodies directly affect efficacy, dose and dose intervals, application route and tissue penetration. In indications where health-care providers and patients can choose between several...
10.
Schadt S, Hauri S, Lopes F, Edelmann M, Staack R, Villasenor R, et al.
Drug Metab Dispos
. 2019 Nov;
47(12):1443-1456.
PMID: 31748266
For therapeutic proteins, the currently established standard development path generally does not foresee biotransformation studies by default because it is well known that the clearance of therapeutic proteins proceeds via...